Patch testing with methyldibromo glutaronitrile, a multicentre study within the EECDRG.
Contact allergy to and allergic contact dermatitis from methyldibromo glutaronitrile (MDBGN) have frequently been reported. As there has been no agreement on which MDBGN test preparation to use, a study was initiated to help determine the optimal patch test preparation for MDBGN. 2661 consecutively patch tested patients at 11 test clinics representing 9 European countries participated. Petrolatum preparations with MDBGN at 1.0%, 0.5%, 0.3% and 0.1% were inserted in the standard series. Contact allergy rates were noted in the range 4.4-1.1% following decreasing test concentrations. Reactions not fulfilling all criteria to be classified as allergic reactions could represent either weak allergic or irritant reactions, and such reactions were noted in the range 8.2-0.5% with decreasing concentrations. A significant number of these reactions represented weak allergic reactions, as allergic reactions were obtained to higher patch test concentrations in the same individual. Morphologically irritant reactions were noted only for the highest test concentrations. In summary, the contact allergy rates and frequencies of doubtful and irritant reactions vary with the patch test concentration. The final decision on patch test concentration for MDBGN should not only rely on these factors but also include information on patch test concentrations required to diagnose individual cases with allergic contact dermatitis from MDBGN as well as results of repeated open application tests.
Gruvberger
B
B
Department of Occupational and Environmental Dermatology, Malmö University Hospital, S-205 02 Malmö, Sweden. birgitta.gruvberger@drm.mas.lu.se
Andersen
K E
KE
Brandão
F M
FM
Bruynzeel
D P
DP
Bruze
M
M
Frosch
P J
PJ
Goossens
A
A
Lahti
A
A
Lindberg
M
M
Menné
T
T
Orton
D
D
Seidenari
S
S
D000485:Allergens / Q000009:adverse effects*; D003358:Cosmetics / Q000009:adverse effects; D017449:Dermatitis, Allergic Contact / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D009570:Nitriles / Q000009:adverse effects*; D010328:Patch Tests / Q000379:methods / Q000592:standards*; D011237:Predictive Value of Tests; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects*; D012107:Research Design
D000485:Allergens; D003358:Cosmetics; D009570:Nitriles; D011310:Preservatives, Pharmaceutical; C039411:1,2-dibromo-2,4-dicyanobutane